Agenus reports Q3 net loss $56.7M, cash $218.2M; botensilimab Phase 2 trials initiated

AGENUS INC

2022-Q3 EPS reported -$0.54 revenue$69,638,000

Q3 2022 net loss $56.7M ($0.19/sh) vs prior-year net income; revenue $22.8M, down from $253M largely due to prior milestone.
Cash and investments $218.2M vs $306.9M at Dec 2021; cash used in operations $32.2M in Q3.
Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and melanoma.
Expanded leadership: Patricia Carlos named Chief Regulatory, Quality & Safety Officer; Todd Yancey as Senior Clinical Advisor.
Partner programs advancing: BMS, Merck, Incyte ongoing Phase 2/1 trials for discovered assets.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AGENUS INC reported the third quarter of 2022 results: revenue $22.8 million, net income $56.7 million, EPS $0.19 per share.

Period: the third quarter of 2022
Revenue: $22.8 million
Net income: $56.7 million
EPS: $0.19 per share
Result: reported results

Exact text from the filing

We recognized revenue of $22.8 million and incurred a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001171843-22-007211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.